Patterns of p53 immunoreactivity in endometrial carcinomas: ‘all or nothing’ staining is of importance

IMP3 Distinguishes Uterine Serous Carcinoma From Endometrial Endometrioid Adenocarcinoma

(2010) Paulette Mhawech-Fauceglia et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Novel staining pattern of p53 in Barrett’s dysplasia - the absent pattern

(2010) Philip V Kaye et al.   HISTOPATHOLOGY

High-Grade Endometrial Carcinoma: Serous and Grade 3 Endometrioid Carcinomas Have Different Immunophenotypes and Outcomes

(2010) Abdulmohsen Alkushi et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY

Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary

(2010) Ahmed Ashour Ahmed et al.   JOURNAL OF PATHOLOGY

The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas

(2010) Martin Köbel et al.   JOURNAL OF PATHOLOGY

The Oncofetal Protein IMP3

(2009) Wenxin Zheng et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Utility of p16 Expression for Distinction of Uterine Serous Carcinomas From Endometrial Endometrioid and Endocervical Adenocarcinomas

(2009) Anna Yemelyanova et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

WT1, p53 and hormone receptor expression in uterine serous carcinoma

(2009) Lynn Hirschowitz et al.   HISTOPATHOLOGY

p53 overexpression in morphologically ambiguous endometrial carcinomas correlates with adverse clinical outcomes

(2009) Karuna Garg et al.   MODERN PATHOLOGY